Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Integrin alpha 4 beta 7

Integrin alpha 4 beta 7

Brief Information

Name:Integrin alpha-4/beta-7
Target Synonym:LPAM-1,Lymphocyte Peyer s patch Adhesion Molecule 1
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
EP-155 Human Integrin α 4 β 7 : MAdCAM-1 [Biotinylated] Inhibitor Screening ELISA Kit
IT7-H52W4 Human Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free (MALS & SPR verified)
IT7-H52W4-structure
IT7-H52W4-sds
ACRO Quality

Part of Bioactivity data

IT7-H52W4-SPR
Integrin alpha 4 beta 7 SPR

Anti-Human Integrin α 4 β 7 MAb, Human IgG1 (ADCC Disable) captured on Protein A Chip can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (IT7-H52W4) with an affinity constant of 1.37 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol
IT7-H52W4-MALS-HPLC
Integrin alpha 4 beta 7 MALS images

The purity of Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) is more than 85% and the molecular weight of this protein is around 210-250 kDa verified by SEC-MALS.

Synonym Name

Integrin alpha 4 beta 7,ITGA4&ITGB7

Background

Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin  alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Vedolizumab MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 Approved Millennium Pharmaceuticals Inc 安吉优, Entyvio United States Colitis, Ulcerative; Crohn Disease Takeda Pharmaceuticals U.S.A. Inc 2014-05-20 Colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Urogenital Neoplasms; Colitis, Ulcerative; Pediatric ulcerative colitis; Celiac Disease; Cholangitis, Sclerosing; Solid tumours; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); HIV Infections Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Multiple Sclerosis; Crohn Disease Biogen Idec 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Vedolizumab MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 Approved Millennium Pharmaceuticals Inc 安吉优, Entyvio United States Colitis, Ulcerative; Crohn Disease Takeda Pharmaceuticals U.S.A. Inc 2014-05-20 Colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Urogenital Neoplasms; Colitis, Ulcerative; Pediatric ulcerative colitis; Celiac Disease; Cholangitis, Sclerosing; Solid tumours; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); HIV Infections Details
Natalizumab biosimilar(Polpharma Biologics) PB-006; DST-356A1 Approved Polpharma Biologics Sa Tyruko United States Crohn Disease; Multiple Sclerosis Sandoz Inc 2023-08-24 Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Llc Tysabri, Antegran, Antegren United States Multiple Sclerosis; Crohn Disease Biogen Idec 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Demyelinating Diseases; Myositis, Inclusion Body; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Phase 3 Clinical Genentech Inc Colitis, Ulcerative; Crohn Disease Details
Vedolizumab biosimilar (Polpharma Biologics) PB-016 Phase 3 Clinical Polpharma Biologics Sa Pouchitis; Colitis, Ulcerative; Crohn Disease Details
MORF-057 MORF-057 Phase 2 Clinical Morphic Therapeutic Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
PN-10943 PN-10943-A; PN-10943; PN-943 Phase 2 Clinical Protagonist Therapeutics Inc Colitis, Ulcerative Details
GS-1427 GS-1427 Phase 2 Clinical Inflammatory Bowel Diseases; Colitis, Ulcerative Details
ABBV-382 Phase 2 Clinical Abbvie Inc HIV Infections Details
PTG-100 PTG-100 Phase 1 Clinical Protagonist Therapeutics Inc Celiac Disease; Colitis, Ulcerative Details
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Phase 3 Clinical Genentech Inc Colitis, Ulcerative; Crohn Disease Details
Vedolizumab biosimilar (Polpharma Biologics) PB-016 Phase 3 Clinical Polpharma Biologics Sa Pouchitis; Colitis, Ulcerative; Crohn Disease Details
MORF-057 MORF-057 Phase 2 Clinical Morphic Therapeutic Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
PN-10943 PN-10943-A; PN-10943; PN-943 Phase 2 Clinical Protagonist Therapeutics Inc Colitis, Ulcerative Details
GS-1427 GS-1427 Phase 2 Clinical Inflammatory Bowel Diseases; Colitis, Ulcerative Details
ABBV-382 Phase 2 Clinical Abbvie Inc HIV Infections Details
PTG-100 PTG-100 Phase 1 Clinical Protagonist Therapeutics Inc Celiac Disease; Colitis, Ulcerative Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap